BioVector? MWCL-1 人類華氏巨球蛋白血癥細(xì)胞系 / MWCL-1 Human Waldenstr?m’s Macroglobulinemia Cell Line

通用定義 / General Definition:

BioVector? MWCL-1 是一種源自華氏巨球蛋白血癥（Waldenstr?m’s Macroglobulinemia, WM）患者外周血的 B 細(xì)胞系。該細(xì)胞系具有典型的漿細(xì)胞樣差異化特征，并攜帶 $MYD88^{L265P}$ 突變。與 BCWM.1 相比，BioVector? MWCL-1 在表型上更接近于漿細(xì)胞階段，是研究 WM 異質(zhì)性、IgM 合成路徑以及腫瘤細(xì)胞與骨髓基質(zhì)相互作用的重要生物學(xué)模型。

BioVector? MWCL-1 is a B-cell line established from the peripheral blood of a patient with Waldenstr?m’s Macroglobulinemia (WM). It exhibits distinct plasmacytoid differentiation features and carries the hallmark $MYD88^{L265P}$ mutation. Compared to BCWM.1, BioVector? MWCL-1 represents a more plasma-cell-like phenotype, making it an essential biological model for studying WM heterogeneity, IgM synthesis pathways, and the interaction between malignant cells and the bone marrow microenvironment.

BioVector? MWCL-1 細(xì)胞系技術(shù)說明書 (Cell Line Datasheet)

中文版說明書

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? MWCL-1 人華氏巨球蛋白血癥細(xì)胞

• 細(xì)胞來源： 人類 (Human)

• 組織來源： 外周血 (Peripheral Blood)

• 生長特性： 懸浮生長 (Suspension)

• 細(xì)胞形態(tài)： 淋巴母細(xì)胞樣/漿細(xì)胞樣

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? RPMI 1640 培養(yǎng)基

• 血清添加： 10% BioVector? 胎牛血清 (FBS)

• 培養(yǎng)環(huán)境： 37°C，5% $CO_2$，飽和濕度

3. 細(xì)胞應(yīng)用

• 疾病模型： 華氏巨球蛋白血癥 (WM) 的分子機(jī)制研究。

• 信號(hào)通路： 探索 $MYD88$ 突變后的下游 TLR 信號(hào)傳導(dǎo)。

• 藥物評(píng)價(jià)： 評(píng)估蛋白酶體抑制劑或新型免疫調(diào)節(jié)藥物對(duì) WM 細(xì)胞的殺傷作用。

4. 注意事項(xiàng)

• 細(xì)胞密度： 為保持最佳生長狀態(tài)，建議維持密度在 $4 \times 10^5$ 至 $1.5 \times 10^6$ cells/mL。

• 分化狀態(tài)： 該細(xì)胞系表現(xiàn)出較強(qiáng)的漿細(xì)胞特征，實(shí)驗(yàn)過程中應(yīng)定期監(jiān)測(cè)其表面標(biāo)記物（如 CD138, CD19, CD20）的表達(dá)情況。

English Datasheet

1. General Product Information

• Product Name: BioVector? MWCL-1 Human Waldenstr?m’s Macroglobulinemia Cell Line

• Organism: Human

• Tissue Source: Peripheral Blood

• Growth Properties: Suspension

• Morphology: Lymphoblast-like / Plasmacytoid

2. Culture Conditions

• Basal Medium: BioVector? RPMI 1640 Medium

• Serum Supplement: 10% BioVector? Fetal Bovine Serum (FBS)

• Incubation: 37°C, 5% $CO_2$, Saturated Humidity

3. Applications

• Disease Modeling: Molecular mechanism studies of Waldenstr?m’s Macroglobulinemia (WM).

• Signaling Pathways: Exploring downstream TLR signaling pathways following $MYD88$ mutation.

• Drug Evaluation: Assessing the efficacy of proteasome inhibitors or novel immunomodulatory agents against WM cells.

4. Key Usage Notes

• Culture Density: To maintain optimal growth, it is recommended to keep the cell density between $4 \times 10^5$ and $1.5 \times 10^6$ cells/mL.

• Differentiation Profile: This cell line exhibits strong plasma cell characteristics; regular monitoring of surface markers (e.g., CD138, CD19, CD20) is advised to ensure phenotypic stability.

Note: BioVector? MWCL-1 cells should be handled strictly under Biosafety Level 2 (BSL-2) guidelines. To maintain the specific metabolic profile and proliferative capacity of these malignant B-cells, the use of BioVector? RPMI 1640 Medium and BioVector? Fetal Bovine Serum is essential.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

E-mail: [email protected]

http://www.nedfriskphoto.com